Last reviewed · How we verify
Corzide (BENDROFLUMETHIAZIDE)
Corzide (BENDROFLUMETHIAZIDE) is a thiazide diuretic medication originally developed by, currently owned by. It targets the solute carrier family 12 member 3 and is a small molecule modality. FDA approved in 1959 for the treatment of hypertensive disorder, Corzide is off-patent with no active Orange Book patents. As a generic medication, it is manufactured by multiple companies. Key safety considerations include monitoring of electrolyte levels and potential side effects such as hypokalemia.
At a glance
| Generic name | BENDROFLUMETHIAZIDE |
|---|---|
| Drug class | Thiazide Diuretic |
| Target | Solute carrier family 12 member 3 |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
| First approval | 1959 |
Approved indications
- Hypertensive disorder
Common side effects
- Bradycardia (heart rate <60 bpm)
- Peripheral vascular insufficiency (Raynaud type)
- Dizziness or fatigue
- Cardiac failure
- Hypotension
- Rhythm/conduction disturbances
- Nausea
- Diarrhea
- Abdominal discomfort
- Constipation
- Vomiting
- Indigestion
Serious adverse events
- Symptomatic bradycardia (heart rate <40 bpm)
- First degree heart block
- Third degree heart block
- Bronchospasm
- Agranulocytosis
- Thrombocytopenic or nonthrombocytopenic purpura
- Mesenteric arterial thrombosis
- Ischemic colitis
- Aplastic anemia
- Anaphylactic reactions
Drug interactions
- dofetilide
- lithium
Key clinical trials
- Mechanisms of Diuretic Resistance in Heart Failure, Aim 2 (PHASE1)
- Mechanisms of Diuretic Resistance in Heart Failure, Aim 3 (PHASE1)
- Fed Study of Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg and Corzide® Tablets 80 mg/5 mg (PHASE1)
- Fasting Study of Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg and Corzide® Tablets 80 mg/5 mg (PHASE1)
- ACEI or ARB and COVID-19 Severity and Mortality in US Veterans
- Coronavirus (COVID-19) ACEi/ARB Investigation (PHASE4)
- A Randomised, Parallel-group, Double-blind, Double-dummy Study to Compare the Effects of Lacidipine Versus Bendrofluazide on Markers of Platelet Activation and Haemorheological Factors in Hypertensive Patients (PHASE4)
- Pathophysiological Mechanisms of Hypertensive LVH:Optimising Regression (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Corzide CI brief — competitive landscape report
- Corzide updates RSS · CI watch RSS